Economic Analysis of Medicare Coverage for GLP-1 Drugs

Research published in the JAMA Health Forum assesses the economic consequences of Medicare covering GLP-1 drugs, specifically for obesity treatment. Utilization by the Centers for Medicare and Medicaid Services (CMS) is projected to elevate Medicare Part D expenditures by approximately $66 billion over a decade, while generating $18 billion in healthcare savings. This results in a net increase of around $48 billion in Medicare expenses. Although these drugs help prevent conditions like heart attacks and kidney failure, the overall cost to Medicare is anticipated to rise. Future studies might reveal additional savings as more health benefits are established.

A report from the Institute for Clinical and Economic Review (ICER) in 2022 determined that over a lifetime, these medications cost about $274,000 while reducing medical expenses by $62,000. ICER found them cost-effective at specified pricing levels: $6,830 for semaglutide and $7,973 for tirzepatide by December 2025. In a 2025 study, JAMA Health Forum calculated the cost per quality-adjusted life year (QALY) for tirzepatide (Zepbound) at $197,000 and for semaglutide (Wegovy) at $468,000, noting that a QALY over $100,000 is generally not deemed cost-effective. Despite some favorable clinical outcomes, like reduced cardiac events, these treatments present a notable economic challenge.

Employers and insurers focusing on GLP-1 medication coverage might observe better employee health and productivity, though not necessarily reduced medical costs. Lowering acquisition costs could improve the financial rationale for coverage. Reports indicate discontinuation of GLP-1 coverage by some insurers, while new market entrants may drive prices down. Further reductions could occur with the approval of generic semaglutide in markets like Canada and India, potentially impacting U.S. pricing dynamics. Current data on prescription trends for these treatments within Medicare’s Bridge program remains unavailable.